Answers are grounded in this paper and cite their sources.
mutations are resistant to everolimus. However, there are no clinical data in breast cancer patients to support this conclusion. Therefore, large-scale clinical studies are needed to identify biomarkers of efficacy and resistance to everolimus.
No takes yet. Share an insight, caveat, or question.
Yi et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: